Aristeia Capital’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Aristeia Capital’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,524,010	Closed	-$15.4M	–	538
2022 Q4	$15.4M	Buy	1,524,010 +375,000	+33%	+$3.75M	0.31%	85
2022 Q3	$11.4M	Hold	1,149,010	–	–	0.2%	144
2022 Q2	$11.4M	Hold	1,149,010	–	–	0.2%	135
2022 Q1	$11.3M	Hold	1,149,010	–	–	0.21%	133
2021 Q4	$11.3M	Buy	+1,149,010	New	+$11.3M	0.2%	135

Aristeia Capital's BIOT Position: Q1 2023 in Review

Aristeia Capital sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 1,524,010 shares — an estimated $15.4M sold.

Aristeia Capital first reported a position in BIOT in Q4 2021 and held it in 5 quarters. The position peaked at $15.4M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Aristeia Capital reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Aristeia Capital sold 1,524,010 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $15.4M.
Aristeia Capital first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 5 quarters.
Aristeia Capital's Biotech Acquisition Company Class A Ordinary Shares position peaked at $15.4M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Aristeia Capital's 13F filing for Q1 2023, filed 16 May 2023.